EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report

Charles R Conway, Scott T Aaronson, Harold A Sackeim, Walter Duffy, Mary Stedman, João Quevedo, Rebecca M Allen, Patricio Riva-Posse, Matthew A Berger, Gustavo Alva, Mohd Azfar Malik, David L Dunner und 14 weitere

Brain Stimulation · 2024

DOI: 10.1016/j.brs.2024.03.016 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Brain Stimulation, 2024. Verfasst von Charles R Conway und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: conwaycr@wustl.edu. Hauptthemen laut MEDLINE: Major Depressive Disorder, Depressive Disorder, Treatment-Resistant, Transcranial Magnetic Stimulation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Centers for Medicare and Medicaid Services, Cerebrotech Medical Systems, LivaNova Plc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: RECOVER is a randomized sham-controlled trial of vagus nerve stimulation and the largest such trial conducted with a psychiatric neuromodulation intervention. OBJECTIVE: To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive disorder (MDD), overall and as a function of exposure to interventional psychiatric treatments (INTs), including electroconvulsive therapy, transcranial magnetic stimulation, and esketamine. METHODS: Medical, psychiatric, and treatment records were reviewed by study investigators and an independent Study Eligibility Committee prior to study qualification. Clinical characteristics and treatment history (using Antidepressant Treatment History [Short] Form) were compared in those qualified (N = 493) versus not qualified (N = 228) for RECOVER, and among the qualified group as a function of exposure to INTs during the current major depressive episode (MDE). RESULTS: Unipolar MDD patients who qualified for RECOVER had marked TRD (median of 11.0 lifetime failed antidepressant treatments), severe disability (median WHODAS score of 50.0), and high rate of baseline suicidality (77% suicidal ideation, 40% previous suicide attempts). Overall, 71% had received at least one INT. Compared to the no INT group, INT recipients were younger and more severely depressed (QIDS-C, QIDS-SR), had greater suicidal ideation, earlier diagnosis of MDD, and failed more antidepressant medication trials. CONCLUSIONS: RECOVER-qualified unipolar patients had marked TRD and marked treatment resistance with most failing one or more prior INTs. Treatment with ≥1 INTs in the current MDE was associated with earlier age of MDD onset, more severe clinical presentation, and greater treatment resistance relative to patients without a history of INT. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03887715.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderDepressive Disorder, Treatment-ResistantTranscranial Magnetic StimulationHumansMaleFemaleMiddle AgedAdultElectroconvulsive TherapyVagus Nerve StimulationAntidepressive AgentsKetamineTreatment Outcome

Stichwörter der Autor:innen

Electroconvulsive therapyEsketamineRECOVER trialTranscranial magnetic stimulation (TMS)Treatment-resistant depression (TRD)Vagus nerve stimulation (VNS)

Substanzen

Antidepressive AgentsKetamineEsketamine

Autor:innen und Institutionen

  • Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: conwaycr@wustl.edu.
  • Department of Clinical Research, Sheppard Pratt Health System, Baltimore, MD, USA.
  • Departments of Psychiatry and Radiology, Columbia University, New York, NY, USA.
  • Alivation Research, Lincoln, NE, USA.
  • Stedman Clinical Trials, Tampa, FL, USA.
  • Center for Interventional Psychiatry, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.

Förderung

  • Centers for Medicare and Medicaid Services
  • Cerebrotech Medical Systems
  • LivaNova Plc

Zitieren

APA

Conway, C. R., Aaronson, S. T., Sackeim, H. A., Duffy, W., Stedman, M., Quevedo, J., Allen, R. M., Riva-Posse, P., Berger, M. A., Alva, G., Malik, M. A., Dunner, D. L., Cichowicz, I., Luing, H., Zajecka, J., Nahas, Z., Mickey, B. J., Kablinger, A. S., Kriedt, C. L., …, & Rush, A. J. (2024). Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report. Brain Stimulation. https://doi.org/10.1016/j.brs.2024.03.016

Vancouver

Conway CR, Aaronson ST, Sackeim HA, Duffy W, Stedman M, Quevedo J, et al. Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report. Brain Stimulation. 2024. doi:10.1016/j.brs.2024.03.016

BibTeX
@article{Conway2024,
  author = {Conway, Charles R and Aaronson, Scott T and Sackeim, Harold A and Duffy, Walter and Stedman, Mary and Quevedo, João and Allen, Rebecca M and Riva-Posse, Patricio and Berger, Matthew A and Alva, Gustavo and Malik, Mohd Azfar and Dunner, David L and Cichowicz, Ivan and Luing, Heather and Zajecka, John and Nahas, Ziad and Mickey, Brian J and Kablinger, Anita S and Kriedt, Christopher L and Bunker, Mark T and Lee, Ying-Chieh Lisa and Shy, Olivia and Majewski, Shannon and Olin, Bryan and Tran, Quyen and Rush, A John},
  title = {Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report},
  journal = {Brain Stimulation},
  year = {2024},
  doi = {10.1016/j.brs.2024.03.016}
}
Kostenlos starten →